Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 8:13:871463.
doi: 10.3389/fimmu.2022.871463. eCollection 2022.

Engineering the common cold to be a live-attenuated SARS-CoV-2 vaccine

Laura M Kasman  1
Affiliations
Review

Engineering the common cold to be a live-attenuated SARS-CoV-2 vaccine

Laura M Kasman. Front Immunol. .

Abstract

According to the American Centers for Disease Control and Prevention, people in all age groups catch two or more "colds" per year, at least half of which are caused by human rhinoviruses. Despite decades of effort, there are no vaccines or drugs against rhinovirus infections and even social distancing measures that were effective in reducing the spread of the pandemic coronavirus, SARS-CoV-2, did not reduce the rate of rhinovirus detection. Fortunately, most rhinovirus strains are naturally attenuated in that they are not associated with serious illness, hospitalization or mortality. Instead, rhinoviruses are one of the most frequent viruses found in nasal swabs of asymptomatic, healthy people. Since rhinovirus infections cannot be avoided, a rational approach would be to engineer them for the benefit of their human hosts. Rhinovirus infections naturally induce robust mucosal and serum immune responses to all virus-expressed proteins. Several replication-competent, human rhinovirus vaccine vectors able to express protective antigens for other pathogens have already been designed and tested in animal models. With this strategy, the inevitable common cold would be able to induce immunity not just to a specific rhinovirus serotype but to other more pathogenic respiratory viruses as well. This article reviews existing rhinovirus vaccine vector technology and describes the characteristics that make live-attenuated rhinoviruses attractive vaccine candidates for SARS-CoV-2 and other pathogenic respiratory viruses in the future.

Keywords: SARS-CoV2; attenuated; human; intranasal vaccination; live vaccine; replication competent; rhinovirus.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect (2022) 28(2):202–21. doi: 10.1016/j.cmi.2021.10.005 - DOI - PMC - PubMed
    1. Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, et al. . Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic. Influenza Other Respir Viruses (2021) 15(4):488–94. doi: 10.1111/irv.12854 - DOI - PMC - PubMed
    1. Cooksey GLS, Morales C, Linde L, Schildhauer S, Guevara H, Chan E, et al. . Severe acute respiratory syndrome coronavirus 2 and respiratory virus sentinel surveillance, California, USA, may 10, 2020-June 12, 2021. Emerg Infect Dis (2022) 28(1):9–19. doi: 10.3201/eid2801.211682 - DOI - PMC - PubMed
    1. Jia R, Lu L, Li S, Liu P, Xu M, Cao L, et al. . Human rhinoviruses prevailed among children in the setting of wearing face masks in shanghai, 2020. BMC Infect Dis (2022) 22(1):253. doi: 10.1186/s12879-022-07225-5 - DOI - PMC - PubMed
    1. Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev (2013) 26(1):135–62. doi: 10.1128/CMR.00077-12 - DOI - PMC - PubMed

Publication types